08.24.2021
Prevent & Delay
$245,080.00
30 months
Generation of a bispecific interleukin-2 immunotherapy for preferential and pancreas-targeted stimulation of regulatory T cells in the treatment of type-1 diabetes mellitus
Funds support activities into designing and preclinically testing a targeted immunotherapy for type 1 diabetes (T1D).